QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides Shareholder Update
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its financial results for the second quarter ended June 30, 2019 and also provided a year-to-date business update. “This year we remained focused on advancing our pipeline,” INmune Bio CEO RJ Tesi, M.D., said in the news release. “More recently we announced we have begun planning a Phase II trial for INB03 after receiving positive preliminary data from its clinical Phase I study. This preliminary data has allowed us to move forward with the development of…